Solid State Screening: Finding the Optimal Crystal Form

Why the First Crystal Form Is Rarely the Right One

When a medicinal chemist synthesises a new active pharmaceutical ingredient for the first time, the crystal form that precipitates out of solution is a function of the solvent system, the temperature, and the rate of crystallisation used. It is rarely the thermodynamically stable form, and it is rarely the form with the best combination of solubility, stability, and processability for a drug product.

Solid state screening is the systematic process of identifying the range of crystal forms a molecule can adopt and selecting the one, or the combination of salt and form, that best supports the target product profile. Getting this right in pre-formulation is one of the highest-value decisions in early drug development. Getting it wrong after GMP manufacturing has started can require a regulatory amendment, a reformulation programme, and a significant delay to the clinical timeline.

What Solid State Screening Covers

Polymorph Screening

Many organic molecules can crystallise in more than one arrangement of molecules in the solid state. These different arrangements, known as polymorphs, have different physical properties including melting point, solubility, dissolution rate, chemical stability, and hygroscopicity. Two polymorphs of the same API can have dramatically different bioavailability profiles. A metastable form that gives excellent dissolution performance in early development may convert to a more stable but less soluble form under the conditions of manufacturing or storage.

Polymorph screening uses a range of crystallisation conditions, solvents, temperatures, and seeding experiments to map the landscape of forms available to a molecule. X-ray powder diffraction (XRPD) is the primary analytical tool for identifying and characterising each form. The ICH Q6A guidance on specifications for new drug substances requires the solid form to be defined and controlled, making this screening work a regulatory necessity as well as a scientific one.

Salt Screening

For ionisable molecules, forming a pharmaceutical salt is often the most effective way to improve aqueous solubility and chemical stability. Salt screening evaluates a range of pharmaceutically acceptable counterions to identify which salt forms are crystalline, physically stable, and give meaningful solubility improvements over the free form. The selection of a salt is also an intellectual property decision: a novel salt form with demonstrated advantages over existing forms may be patentable, extending the effective commercial life of the molecule.

Solvate and Hydrate Assessment

Some molecules preferentially incorporate solvent or water molecules into their crystal lattice, forming solvates or hydrates. These forms can be more stable than anhydrous forms under certain conditions, or they can be a liability if they dehydrate or desolvate during processing. Understanding which solvated forms exist, and under what conditions they are stable, is part of a complete solid state assessment.

Key Solid State Forms and Their Implications

Form Type	Definition	Key Implication for Development
Polymorph	Different crystal packing of the same molecule	Can affect solubility, stability, and bioavailability. Must be controlled in the GMP process.
Salt	Ionic form with a pharmaceutically acceptable counterion	Often improves solubility and stability. May be patentable.
Cocrystal	Non-ionic multicomponent crystal with a coformer	Useful for non-ionisable molecules. Can improve physical properties.
Solvate / Hydrate	Crystal lattice containing solvent or water	Can be stable or unstable depending on humidity. Must be assessed during stability studies.
Amorphous	Non-crystalline solid form	Higher energy state, typically higher solubility but lower stability. Requires stabilisation strategy.

The IP Dimension of Solid State Work

Beyond the formulation and regulatory arguments for thorough solid state screening, there is a commercial argument that is often underappreciated at the early development stage. A patent covering a novel salt form, polymorph, or cocrystal of a development-stage API can significantly extend the period of market exclusivity beyond the composition of matter patent. This is not a secondary consideration. For molecules in highly competitive therapeutic areas, the solid form patent strategy can be as commercially important as the clinical development programme.

Ardena’s solid state research team works closely with clients to ensure that screening work is conducted in a way that generates patentable data where the science supports it, and that the relationship between solid form, IP strategy, and regulatory filing is considered from the outset.

Ardena’s Solid State Research Capabilities in Ghent

Ardena’s solid state research team in Ghent conducts polymorph screening, salt selection, cocrystal screening, and hydrate/solvate assessment using a combination of high-throughput crystallisation and advanced characterisation techniques. XRPD, differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and dynamic vapour sorption (DVS) are used to characterise each form and assess its stability under relevant conditions.

The solid state data generated in Ghent is directly connected to the drug product formulation work, meaning that form selection decisions are made with the full development context in mind, not in isolation. This integration is particularly valuable when the optimal form for stability conflicts with the optimal form for dissolution, and a scientifically informed compromise is required.

Building Resilient Supply Chains for Rare Disease Drugs

Rare Disease Development Is a Different Kind of Problem

The clinical supply challenges in rare disease drug development are categorically different from those in standard pharmaceutical programmes. Patient populations are small, sometimes in the dozens rather than the thousands. The drug may be highly potent, genetically targeted, or manufactured using a technology platform with limited redundancy. Each individual dose can represent a disproportionately high cost relative to conventional therapeutics. And the consequence of a supply failure is not a delayed commercial shipment but a delayed patient dose that may have no alternative.

Building a resilient supply chain for a rare disease programme requires a different mindset and, often, a different type of CDMO partner.

The Specific Challenges of Rare Disease Supply

Small Batch Sizes

Standard GMP manufacturing processes and equipment are optimised for batch sizes that may be many times larger than what a rare disease programme requires. Running small batches efficiently, without compromising yield, analytical testing coverage, or the cost-per-dose economics, requires manufacturing processes specifically designed for small-scale production. Not all CDMOs have the equipment configuration and operational experience to do this well.

High-Value API Management

In a rare disease programme, the drug substance is often extremely expensive to produce. A failed GMP batch does not just mean a delay. It may mean a six-month wait for the next batch of API. Supply chain resilience therefore starts with process robustness: ensuring that the manufacturing process has sufficient design space that it succeeds reliably rather than at the limits of its capability.

Adaptive Trial Design Complexity

Many rare disease clinical trials use adaptive designs that allow the protocol to be modified based on interim data. From a supply chain perspective, this creates planning complexity: you need to hold enough clinical supply to support protocol expansions or changes, while avoiding overproduction of a high-cost drug for a small patient population. EMA guidance on adaptive trial designs acknowledges the particular challenges of adaptive studies and provides a framework for managing the interaction between trial design and drug supply.

Global Distribution to Low-Volume Sites

Phase II and III trials in rare diseases often require distribution to clinical sites across multiple countries, each receiving very small quantities of study drug. Standard clinical supply logistics assume larger shipments to more sites. Rare disease supply chains need solutions that can handle country-specific regulatory requirements, small-parcel cold chain, and the documentation requirements of each jurisdiction without the economies of scale that come with conventional clinical supply.

Rare Disease Supply Chain: Key Capability Requirements

Capability	Why It Matters for Rare Disease	Ardena Capability
Small-batch GMP manufacturing	Patient populations may require fewer than 100 doses per batch	Available across Ghent, Pamplona, and Oss sites
HPAPI handling	Many rare disease drugs are highly potent	OEB 3-5 containment available at Pamplona
Lyophilisation	Common formulation strategy for biologic rare disease drugs	Available at Ghent
Clinical packaging and labelling	Complex country-specific requirements for small volumes	Available at Ghent and Assen
Stability management	Long-duration stability to support extended trial periods	GMP stability storage across multiple sites
CMC regulatory writing	Orphan designation has specific CMC implications	Integrated regulatory team, multi-jurisdictional experience

The Orphan Drug Designation Dimension

Orphan Drug Designation (ODD), available through both the FDA and EMA, provides significant incentives for rare disease drug development, including fee waivers, regulatory assistance, and market exclusivity on approval. The designation also has CMC implications. The EMA’s ODD criteria include a requirement to justify the patient population size, and the CMC package for an orphan drug application may be reviewed with different data expectations than a standard application.

Ardena’s regulatory team has experience preparing CMC packages for programmes with orphan designation across both jurisdictions. Our related article on Preparing Module 3 of the CTD: A Practical Guide covers the CMC filing requirements relevant to rare disease programmes.

How Ardena Supports Rare Disease Programmes

Ardena’s manufacturing facilities are configured to handle small-batch GMP production efficiently, including for high-potency compounds at the Pamplona site and for complex injectables and lyophilised products at Ghent. The clinical supply team at Assen manages clinical packaging, labelling, and distribution across multiple markets for programmes with complex logistics requirements.

For rare disease programmes at any stage of development, Ardena’s integrated model means that the manufacturing strategy, the regulatory approach, and the clinical supply plan are developed together rather than sequentially, reducing the risk of misalignment that can cause delays at the worst possible moment.

Sustainability in Pharma Manufacturing: Green Chemistry Trends

The Industry’s Environmental Challenge

Pharmaceutical manufacturing is resource intensive. Organic synthesis generates solvent waste. GMP facilities consume significant energy for temperature and humidity control. Global clinical supply chains generate carbon through international shipping. For an industry that exists to improve human health, the environmental cost of drug production is an increasingly visible contradiction.

This tension is not new, but the pressure to address it has accelerated significantly. Investor ESG frameworks, regulatory agency guidance on environmental risk assessment, and the industry’s own sustainability commitments are all pushing pharmaceutical companies and their outsourcing partners towards greener manufacturing practices. The American Chemical Society’s 12 Principles of Green Chemistry provide a widely used framework for evaluating and improving the environmental performance of chemical processes.

Where Green Chemistry Applies in Drug Development

Solvent Selection and Recovery

Solvents account for a significant proportion of the waste generated in pharmaceutical synthesis. Green chemistry approaches prioritise the use of less hazardous solvents, the recovery and recycling of solvents where technically feasible, and the substitution of traditional solvents with greener alternatives from established solvent selection guides. Several regulatory agencies now expect sponsors to address solvent choice in their CMC narratives.

Process Efficiency and Atom Economy

Atom economy, the proportion of the atoms in the starting materials that end up in the final product, is a core green chemistry metric for synthetic routes. A route with high atom economy generates less waste per kilogram of product and typically requires fewer purification steps. Evaluating synthetic routes against green chemistry metrics during process development, rather than at scale-up, reduces the cost of improvement.

Energy Intensity in GMP Manufacturing

Heating, cooling, and environmental control systems in GMP facilities are major energy consumers. Equipment upgrades, heat recovery systems, and process optimisation to reduce cycle times all contribute to reducing energy intensity per batch. For manufacturers working with thermolabile products, the energy cost of cold chain storage and distribution is an additional area of focus.

Green Chemistry Metrics in Pharmaceutical Development

Metric	What It Measures	Industry Benchmark
Process Mass Intensity (PMI)	Total mass in divided by mass of product	Industry mean: 200-300 for drug substance; target below 100
E-factor	Mass of waste per mass of product	Fine chemicals: 5-50; pharmaceuticals: 25-100
Solvent intensity	Solvent mass per kg of API	Reduction targets vary by synthesis complexity
Carbon footprint per batch	CO2 equivalent across utilities and logistics	Measured against baseline year; reduction targets per ESG policy

Note: industry benchmarks cited above are drawn from published ACS Green Chemistry and Pharmaceutical Roundtable data and represent general ranges rather than regulatory requirements.

Ardena’s Approach to Sustainable Manufacturing

Ardena is committed to reducing the environmental impact of its manufacturing operations across all sites. In chemical synthesis, this includes evaluating solvent selection as part of process development, with a preference for solvents in the preferred and usable categories of established selection guides. Process analytical technology (PAT) tools used in Ardena’s manufacturing facilities contribute to reduced waste by enabling real-time release and reducing the need for rework.

For biotech companies with sustainability commitments to their investors or stakeholders, partnering with a CDMO that takes environmental performance seriously is an increasingly practical requirement. Ardena’s scientific teams are happy to discuss process development approaches that align with your organisation’s green chemistry objectives.

Navigating the European CDMO Landscape: EU vs. US Regulations

Why the Geography of Your CDMO Partner Matters

The choice to develop a drug in Europe rather than the United States is not just a matter of geography. It affects your regulatory strategy, your manufacturing standards, the reference points in your CMC dossier, and ultimately the timeline to your first clinical data. For many biotech companies, particularly those seeking approval in both markets, understanding the interplay between EMA and FDA requirements from the outset saves significant rework later.

Key Regulatory Differences: EMA vs. FDA

Regulatory Element	EMA (European)	FDA (United States)
Pre-clinical to Phase I submission	IMPD (Investigational Medicinal Product Dossier) in CTD format	IND (Investigational New Drug application)
GMP standard	EU GMP (EudraLex Vol 4)	cGMP (21 CFR Parts 210/211)
Regulatory inspection framework	National Competent Authorities + EMA	FDA CDER/CBER inspection
CMC data expectations at Phase I	Pragmatic; fit-for-purpose with defined limitations	Similar; FDA responsive to first-cycle CMC deficiency letters
Paediatric obligation	Paediatric Investigation Plan (PIP) required	Paediatric Study Plan (PSP) under PREA
Advanced therapy products	ATMP Regulation (1394/2007), CAT committee	BLA/NDA process through CBER
Clinical trial authorisation	Single CTA per Member State or EU CTA (CTIS)	IND filing covers US clinical sites

The Advantages of Developing in Europe

EU GMP Is Recognised Globally

EU GMP certification is accepted by a wide range of health authorities beyond Europe, including those of Australia, Canada, Japan, and many emerging markets. Developing under EU GMP from the outset means your manufacturing data is audit-ready for more markets without additional inspection overhead. The EU GMP mutual recognition agreements with the FDA and other agencies further reduce duplication for globally-focused programmes.

Parallel IMPD/IND Submissions Are Achievable

For companies targeting both EU and US clinical trials, a well-structured CMC dossier developed in Europe can form the basis of both an IMPD and an IND submission. The CTD format (Common Technical Document) was designed precisely to enable this, with Module 3 quality data common to both applications. A CDMO with experience in dual submissions can build that efficiency into the development plan from the start.

Cost-Effective Early Development

For pre-clinical and Phase I work, European CDMOs often offer highly competitive pricing relative to comparable US facilities, with equivalent or superior scientific capabilities. For a capital-efficient biotech, that cost advantage at the development stage can meaningfully extend the runway to the next funding milestone.

How Ardena Supports Multi-Jurisdictional Programmes

Ardena’s facilities are authorised under EU GMP and operate within regulatory environments that are routinely inspected by national competent authorities across Belgium, the Netherlands, Spain, and the US FDA. The organisation has experience preparing CMC sections for both IMPD and IND submissions, and can advise on where regulatory strategies diverge between jurisdictions.

For programmes seeking to run EU and US trials in parallel, Ardena’s regulatory team can help structure the CMC development plan to produce data that satisfies both agencies without duplicating the experimental work

The Importance of Project Management in CDMO Partnerships

Where Outsourced Programmes Actually Go Wrong

In a post-mortem analysis of delayed pharmaceutical development programmes, the root cause is rarely technical. It is almost always communication. The formulation team changed the API particle size specification but did not formally notify the manufacturing team. The client expected a stability report in a format that the CDMO was not using. A critical experiment was delayed because no one flagged the resource conflict two weeks in advance.

None of these are scientific failures. They are project management failures, and they are extraordinarily common in pharma outsourcing relationships.

What Good Project Management Looks Like in CDMO Partnerships

A Single Named Point of Contact

The most important feature of a well-managed CDMO partnership is having one person who owns the programme. Not a team. Not a department. One named project manager who attends every meeting, tracks every deliverable, and is accountable to the client for the health of the programme. When issues arise, you know exactly who to call, and that person knows exactly what is happening across every workstream.

Structured Reporting Cadence

Regular progress reports, written to a consistent template, give clients a clear view of what has been completed, what is in progress, and what is at risk. The best CDMOs produce reports that are informative regardless of whether everything is on track, because they flag emerging issues before they become urgent.

Proactive Risk Escalation

A CDMO project manager who only tells you about problems when they have already happened is not managing risk, they are reporting it. Proactive risk management means identifying the issues that could arise two to four weeks ahead and communicating them to the client in time for mitigation decisions to be made.

Common Failure Modes in CDMO Communication

Failure Mode	Consequence	Prevention
Multiple CDMO contacts with no clear owner	Conflicting information, unclear accountability	Assign a single project manager before work starts
Infrequent or reactive reporting	Delays surface late, options for recovery are limited	Agree reporting frequency and template at kick-off
Scope changes handled informally	Undocumented changes create disputes	Formal change control with written approvals
Technical decisions made without client visibility	Downstream surprises in GMP or dossier	Decision log shared with client in real time
No escalation path defined	Issues stall because no one has authority to resolve them	Agree named escalation contacts at both organisations

How Ardena’s Project Management Model Works

Every Ardena programme is assigned a dedicated project manager from kick-off through to delivery. That person is responsible for coordinating work across Ardena’s scientific teams, maintaining the programme timeline, and communicating progress to the client on an agreed schedule.

Ardena operates a formal change control system that ensures any modification to scope, timeline, or specification is documented and agreed before implementation. Programme status meetings are structured around a consistent agenda, and risk items are flagged in writing rather than raised informally in calls.For complex multi-site programmes, the project manager acts as the interface between Ardena’s facilities, ensuring that work in Ghent, Oss, Assen, and Pamplona is coordinated and progresses in alignment with the overall programme plan.

Risk Mitigation in Early-Stage Drug Development

The Cost of Finding Problems Late

In pharmaceutical development, the same problem costs vastly different amounts depending on when it surfaces. A solubility issue identified during pre-formulation screening costs a few weeks and a reformulation study. The same issue discovered during a GMP manufacturing campaign costs that, plus the failed batch, plus the regulatory amendment, plus the delay to your clinical timeline.

Early-stage drug development is fundamentally about de-risking. The goal is to surface the problems that could derail your programme when they are still cheap to fix, and to build the evidence base that lets you move into GMP manufacturing with confidence.

The Most Common Formulation Showstoppers

Risk Category	Common Manifestation	When It Surfaces Without Mitigation	Mitigation Approach
Poor aqueous solubility	Drug precipitates in dissolution, low bioavailability	Phase I PK disappointment	BCS classification, solubility screening, ASD or nanosuspension strategy
Polymorphic instability	Crystal form converts during processing or storage	Stability failure post-GMP	Polymorph screening, XRPD monitoring, controlled manufacturing conditions
Chemical instability	API degrades under heat, light, or humidity	OOS stability data	Stress testing, excipient compatibility, packaging selection
Manufacturability issues	Blend flows poorly, tablets cap or laminate	Failed GMP batch	Small-scale feasibility studies, equipment-specific evaluation
Bioavailability gap	Animal PK does not translate to human	Phase I PK/PD failure	Human-predictive dissolution, in vitro in vivo correlation modelling

Building a De-Risking Strategy for Your Molecule

Start with the Physical Chemistry

Before any formulation work begins, a thorough characterisation of the API’s physical chemistry is essential. Solubility across the pH range relevant to the GI tract, log P or log D, pKa, melting point, thermal behaviour, and hygroscopicity all inform which formulation strategies are viable and which are not. ICH Q6A provides the quality test procedures framework for new drug substances that underpins this characterisation work.

Do Not Skip Solid-State Screening

The crystal form you first synthesise is rarely the best one for a stable, manufacturable drug product. Polymorph screening identifies the energetically stable forms and establishes which form you are working with. Salt selection can dramatically improve solubility and chemical stability. Conducting this work early, before a crystalline form becomes locked into your process, avoids expensive changes later.

Stress Testing Before GMP

Accelerated and stress stability studies run at high temperature, humidity, and under photolytic conditions are a standard way to predict the degradation behaviour of a new molecule and its formulated product. Running abbreviated stress studies before committing to a formulation approach is a low-cost insurance policy against stability surprises in GMP storage.

How Ardena Builds De-Risking into Every Programme

Ardena’s development programmes are structured around progressive de-risking. The solid-state research team in Ghent conducts polymorph and salt screening as an integrated part of the formulation strategy, not as a standalone activity. The analytical teams develop methods that are fit for purpose at each stage, rather than designing GMP-validated methods before the formulation is stable.

When pre-formulation data suggests a solubility challenge, the team can draw on a range of enabling technologies, including amorphous solid dispersions by spray drying or hot melt extrusion, nanosuspensions, and lipid-based formulations, depending on the molecule’s properties and the target product profile.

Due Diligence Checklist for Phase I CDMO Selection

Why CDMO Selection Deserves More Due Diligence Than It Usually Gets

Choosing a contract development and manufacturing partner for a Phase I programme is one of the most consequential decisions an early-stage drug developer makes. It shapes your timelines, your CMC package, and your ability to respond when something unexpected happens. Yet many biotech companies spend more time evaluating clinical CROs than they spend evaluating their CDMO.

This checklist covers the questions that experienced drug developers ask when evaluating a CDMO for first-in-human manufacturing. It is not exhaustive, but it addresses the areas where gaps most often lead to problems.

Phase I CDMO Evaluation Checklist

Evaluation Area	Key Questions to Ask
GMP compliance	When was the last regulatory inspection? What were the findings? Is the facility authorised for clinical manufacturing?
Quality management system	What is the process for out-of-specification results? How are deviations investigated and closed?
Technical capability	Does the CDMO have experience with your dosage form and route of administration? What formulation technologies are available in-house?
Analytical services	Can the CDMO develop and validate your release methods in-house? How are stability studies managed?
CMC regulatory support	Does the CDMO have experience writing IND/IMPD CMC sections? Can it provide regulatory advice as well as manufacturing?
Project management	Who is your primary contact? How is communication structured? What does the escalation path look like?
Capacity and lead times	What is the current production schedule? What is the realistic timeline from project kick-off to GMP batch?
Supply chain visibility	Where do excipients and starting materials come from? What is the contingency for supplier issues?
Track record	How many Phase I batches has the facility produced in the last two years? Can it provide client references?
Flexibility for change	How does the CDMO handle formulation changes mid-programme? What is the process for scope adjustments?

The Questions Most People Forget to Ask

What Happens When the Project Manager Leaves?

In a small CDMO, the quality of your experience often depends on one or two key people. It is worth asking directly what the continuity plan is if your primary contact leaves the organisation during your programme. An organisation with robust knowledge management systems will have a clear answer.

How Does the CDMO Handle Competing Priorities?

CDMOs work with multiple clients simultaneously. When your programme and a higher-priority client need the same piece of equipment or the same specialist at the same time, something has to give. Ask how the CDMO manages competing priorities and what commitments it makes regarding dedicated capacity.

What Does ‘We Can Do That’ Actually Mean?

Some CDMOs have broad service lists but narrow actual capabilities. If a service is listed but has only been performed once or twice, the learning curve comes at your expense. Ask for the number of programmes completed using the specific technology relevant to your molecule.

How Ardena Approaches Phase I Partnerships

Ardena’s Phase I manufacturing capabilities span oral solids, complex injectables, and nanomedicines across its European network. Each programme is managed by a dedicated project manager and supported by a scientific team that has been involved from early development. The CMC regulatory function is integrated, so the team producing your GMP batches is aligned with the team writing your IND or IMPD CMC section.

The Hidden Costs of Multi-Vendor Outsourcing

The Cheapest Quote Is Not Always the Cheapest Programme

When a biotech company evaluates its outsourcing options, the instinct is often to find the best vendor for each individual piece of work. The best formulation house for development, the best API lab for synthesis, the best analytical CRO for method validation, and the best CMO for GMP manufacture. On paper, combining specialists seems logical. In practice, it generates a category of cost that almost never appears in the project budget: coordination overhead.

This article looks at the real cost of managing multiple vendors across a pharmaceutical development programme, and why an increasing number of drug developers are consolidating with integrated partners to reduce it.

The Management Tax

Every vendor in your programme needs a relationship owner. Someone on your team who attends the technical meetings, reviews the reports, chases the timelines, and translates between the scientific language used by each organisation. If your programme involves four vendors, you need four of those relationships running in parallel, each generating governance overhead.

For a small biotech with a lean team, that overhead is disproportionately expensive. A programme director spending 40% of their time on vendor coordination is not spending 40% of their time on the science. That is a real cost, even if it does not appear on any invoice.

Where Multi-Vendor Costs Actually Show Up

Cost Category	Multi-Vendor Impact	Integrated CDMO Impact
Project management time	High: separate meetings, reports per vendor	Low: single project manager, one reporting cadence
Quality agreement negotiation	Multiple QAs, each requiring legal review	One master QA, updated by amendment
Data reconciliation	Manual collation across systems and formats	Single data environment or coordinated transfer
Tech transfer delays	Required at each handoff	Internal process, no formal transfer
Issue escalation	Multi-party liability discussions	Internal resolution, faster timelines
CMC dossier assembly	Data from 4+ sources, format inconsistencies	Single organisation, consistent format

The Quality Risk That Is Harder to Quantify

Beyond the time costs, multi-vendor programmes carry a qualitative risk that is difficult to put a number on. When something goes wrong in a development programme, and in early-stage development something almost always does, the first question is which vendor is responsible. That question becomes harder to answer when multiple organisations have touched the molecule at different stages, and the answer shapes who bears the cost of fixing it.

The ICH Q10 pharmaceutical quality system framework emphasises the importance of clear knowledge ownership throughout the product lifecycle. Multi-vendor models create structural ambiguity around that ownership, particularly at the interfaces between organisations.

What Consolidation Looks Like with Ardena

Ardena’s multi-site network is designed to serve as a single development and manufacturing partner for the full pre-clinical to clinical journey. Drug substance work, formulation development, analytical services, and GMP manufacturing operate within the same quality system and project management framework. For a programme that might otherwise involve three or four separate vendors, consolidating with Ardena means one quality agreement, one project manager, one reporting cadence, and one organisation accountable for the outcome.

Integrated CDMO Model: Reducing Tech Transfer Friction

The Hidden Cost That Nobody Puts in the Budget

When a drug development team builds a plan for getting from lead candidate to Phase I, they typically account for formulation development costs, GMP manufacturing costs, analytical work, and regulatory fees. What rarely appears on the spreadsheet is the cost of moving data and processes between vendors.

Technology transfer, the act of handing a process from one organisation to another so that it can be reproduced under GMP conditions, is one of the most reliable sources of delay in pharmaceutical development. It is rarely catastrophic on its own, but it consistently adds weeks and months that were not planned for, and the friction compounds across every handoff.

What Actually Goes Wrong in a Tech Transfer

Documentation Gaps

A formulation scientist who developed a process knows things that are not written down. They know which step needs careful attention, which parameter drifts if the ambient temperature changes, and what the analytical method looked like in its early iterations. When that knowledge has to be formalised and transmitted to a new team at a different organisation, some of it is always lost.

Analytical Method Inconsistencies

Drug substance and drug product often use overlapping analytical methods, but those methods may have been developed by different teams working in different labs with different equipment. Reconciling them at the point of tech transfer can take weeks, particularly if one set of methods was designed for a research context and needs to be translated into a GMP-validated form.

Communication Overhead

Every time there is an unexpected result during tech transfer, a question needs to go back to the originating organisation, get answered by someone who may no longer be the primary contact for that programme, and be interpreted by a new team. That loop takes time. ICH Q10 on pharmaceutical quality systems acknowledges the importance of knowledge management precisely because of how often valuable process understanding is lost at organisational boundaries.

The Integrated Model: What It Means in Practice

An integrated CDMO is one where drug substance development, drug product formulation, analytical services, and GMP manufacturing sit within the same organisation, connected by shared systems, shared data, and shared project management. The scientist who identifies the optimal crystalline form in pre-formulation is connected to the team that formulates the drug product, which is connected to the team that executes the GMP campaign.

The transfer is not eliminated. It is replaced by a conversation.

Timeline Comparison

Transfer Step	Multi-Vendor Timeline	Integrated CDMO Timeline
API process transfer	4-8 weeks	No transfer required
Analytical method handover	3-6 weeks	Same team, same systems
Formulation tech transfer	6-10 weeks	Continuous, no formal step
CMC data consolidation	4-6 weeks	Ongoing, one dossier
Total additional time	17-30 weeks	0-2 weeks (internal review)

The timeline figures above represent typical ranges based on industry experience with multi-vendor and integrated outsourcing models. Actual timelines depend on the complexity of the programme and the quality of the originating technical package.

How Ardena’s Multi-Site Model Delivers Integration

Ardena’s facilities are not independent sites operating under a shared brand. They are connected nodes in a single development and manufacturing network. The solid-state research team in Ghent feeds its polymorph and salt screening data directly into the drug product formulation work. The analytical team in Assen uses methods that are coordinated with the analytical groups in other sites from the start of a programme.

When a project moves from preclinical development into GMP manufacturing, the same project manager who has been running the programme continues to own it. There is no formal handover between a development team and a manufacturing team, because they are part of the same organisation.This is what Ardena means when it describes a ‘molecule to patient’ approach. It is not a marketing phrase. It is a structural commitment to keeping the people who understand your molecule involved throughout its development. See our related article on what to look for when selecting a Phase I CDMO for a practical checklist of questions to ask potential partners about their integration model.

The Analytical Blind Spot: Resolving the Matrix Complexities of Nanomedicine Payloads

Developing complex nanomedicines like lipid nanoparticles (LNPs) and polymeric micelles introduces unique challenges for traditional bioanalytical validation. In conventional small-molecule formulations, quantifying drug concentrations is a straightforward process of extraction and chromatographic resolution. However, within a nanomedicine matrix, the active pharmaceutical ingredient (API) exists in a dynamic equilibrium, partitioned between an encapsulated core and an unbound, free fraction in the surrounding continuous phase.

This dual-state environment creates significant hurdles for accurate payload quantification. Standard bioanalytical assays often fail to differentiate between the therapeutic cargo that is safely enclosed within the nanoparticle shell and the fraction that has prematurely leaked into the matrix.

If your bioanalytical characterisation methods lack sufficient resolving power, the resulting data can misrepresent the drug’s true stability, leading to skewed pharmacokinetic models and unpredictable toxicity data during preclinical evaluation. To satisfy global regulatory bodies, drug innovators must implement sophisticated sample preparation and analytical workflows that can isolate and quantify these distinct payload populations without disrupting the fragile colloidal assembly.

Best Practices for Physical and Chemical Characterisation: Quantifying Encapsulation and Release Profiles

Accurately mapping the critical quality attributes (CQAs) of a nanomedicine requires a coordinated combination of physical particle sizing and high-resolution chemical separation. Developers must deploy validated methods to track particle behavior alongside precise payload mass balance calculations.

Characterisation Endpoint	Primary Biophysical Driver	Core Analytical Methodology
Hydrodynamic Diameter & PDI	Monitors particle size distribution, physical stability, and potential aggregation over time.	Dynamic Light Scattering (DLS analysis) and Multi-Angle Laser Light Scattering (MALLS).
Encapsulation Efficiency (EE%)	Determines the percentage of total API successfully entrapped within the nanostructure matrix.	Ultrafiltration centrifugation or Solid-Phase Extraction (SPE) paired with high-sensitivity UPLC-MS/MS.
In Vitro Release Kinetics	Evaluates the desorption and diffusion rate of the active payload under simulated physiological conditions.	Dialysis membrane testing or continuous-flow cell systems coupled with automated fraction collection.
Surface Charge Transition	Tracks the ionisation state of functional lipids across changing localized pH environments.	Zeta Potential analysis via Phase Analysis Light Scattering (PALS).

Determining the true encapsulation efficiency depends entirely on the speed and gentleness of the initial separation step. If the separation process exerts excessive mechanical pressure or shear stress, the nanoparticle shell can rupture, causing artificial payload leakage and underestimating the true encapsulation efficiency.

Similarly, performing reliable DLS analysis requires precise sample dilution protocols. If a suspension is overly concentrated, multiple scattering events will distort the light signal, leading to inaccurate polydispersity index (PDI) readouts and masking small populations of aggregated particles.

At our nanomedicine and bioanalytical CRO center in Oss, The Netherlands, we resolve these challenges by combining non-destructive separation tools, such as Asymmetric Flow Field-Flow Fractionation (AF4), with high-sensitivity mass spectrometry. This allows us to separate free and bound fractions under low-shear conditions, delivering highly reproducible quantification data.

Maximizing Data Integrity: Ardena’s Unified Bioanalytical and Nanomedicine Formulation Platform

Sourcing your nanoparticle manufacturing from one contract vendor and shipping samples to an isolated bioanalytical CRO for stability and payload testing introduces significant risk. Nanomedicine samples are highly sensitive to temperature shifts, vibration, and storage duration. The time elapsed during cross-border transit can trigger premature lipid oxidation, cargo leakage, or structural degradation, resulting in analytical data that no longer reflects the true state of the manufactured batch.

Ardena eliminates these operational risks by integrating process development, cGMP manufacturing, and advanced bioanalytical characterisation under a single quality management system. Based entirely at our specialized nanomedicine facility in Oss, our bioanalytical teams work alongside our formulation engineers in real time. We analyze your critical samples immediately after processing, eliminating transit-induced artifacts and securing your proprietary intellectual property.

Our laboratories are equipped with high-containment infrastructure designed to safely handle high-potency APIs (HPAPIs) and complex injectables. By maintaining a direct data loop between our DLS analysis suites, continuous flow manufacturing lines, and validated UPLC-MS/MS systems, we rapidly track release kinetics and encapsulation efficiency throughout the scale-up process. This integrated approach ensures a completely traceable history for your molecule, generating the robust data packages required to confidently advance through Phase I clinical trials.